Khalil Ramadi

Dr. Khalil Ramadi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CDCanan Dagdeviren
Canan Dagdeviren
KRKhalil Ramadi
Khalil Ramadi
PJPauline Joe
Pauline Joe
KSKevin Spencer
Kevin Spencer
HSHelen N. Schwerdt
Helen N. Schwerdt
RLRobert Langer
Robert Langer
An implantable, remotely controllable, miniaturized drug delivery system permits dynamic adjustment of therapy with a pinpoint spatial accuracy in the brain.

26 April 2023 in Science Robotics
Verified
Journal Article
Closed access
KRKhalil Ramadi
Khalil Ramadi
JMJames C. McRae
James C. McRae
GSGeorge Selsing
George Selsing
ASArnold Su
Arnold Su
RFRafael Fernandes
Rafael Fernandes
GTGiovanni Traverso
Giovanni Traverso
The gut-brain axis, which is mediated via enteric and central neurohormonal signaling, is known to regulate a broad set of physiological functions from feeding to emotional behavior. Various pharmaceuticals and surgical interventions, such as motility agents and bariatric surgery, are used to modulate this axis. Such approaches, however, are associated with off-target effects or post-procedure recovery time and expose patients to substantial risks. Electrical stimulation has also been used to attempt to modulate the gut-brain axis with greater spatial and temporal resolution. Electrical stimulation of the gastrointestinal (GI) tract, however, has generally required invasive intervention for electrode placement on serosal tissue. Stimulating mucosal tissue remains challenging because of the presence of gastric and intestinal fluid, which can influence the effectiveness of local luminal stimulation. Here, we report the development of a bioinspired ingestible fluid-wicking capsule for active stimulation and hormone modulation (FLASH) capable of rapidly wicking fluid and locally stimulating mucosal tissue, resulting in systemic modulation of an orexigenic GI hormone. Drawing inspiration from Moloch horridus, the “thorny devil” lizard with water-wicking skin, we developed a capsule surface capable of displacing fluid. We characterized the stimulation parameters for modulation of various GI hormones in a porcine model and applied these parameters to an ingestible capsule system. FLASH can be orally administered to modulate GI hormones and is safely excreted with no adverse effects in porcine models. We anticipate that this device could be used to treat metabolic, GI, and neuropsychiatric disorders noninvasively with minimal off-target effects.

1 December 2020 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
KRKhalil Ramadi
Khalil Ramadi
SSShriya S. Srinivasan
Shriya S. Srinivasan
GTGiovanni Traverso
Giovanni Traverso

9 February 2023 in Green Chemistry
Verified
Journal Article
Closed access
PDF file
MAMohammed Abdelhameed
Mohammed Abdelhameed
MEMahmoud Elbeh
Mahmoud Elbeh
NBNavajit S. Baban
Navajit S. Baban
LPLeticia Pereira
Leticia Pereira
JMJulie Matula
Julie Matula
KRKhalil Ramadi
Khalil Ramadi
The COVID-19 pandemic has led to unprecedented demand for single-use plastics such as plastic bags and surgical masks. Here we report a one-step, contamination-resistant hydrothermal process to convert waste plastics into carbon dots.

Verified
Journal Article
Open access
PDF file
PAPriyanka Aryappalli
Priyanka Aryappalli
KSKhadija Shabbiri
Khadija Shabbiri
RMRazan Masad
Razan Masad
RARoadha H. Al-Marri
Roadha H. Al-Marri
SHShoja Mohammed Haneefa
Shoja Mohammed Haneefa
BABasel al-Ramadi
Basel al-Ramadi
Aberrantly high levels of tyrosine-phosphorylated signal transducer and activator of transcription 3 (p-STAT3) are found constitutively in ~50% of human lung and breast cancers, acting as an oncogenic transcription factor. We previously demonstrated that Manuka honey (MH) inhibits p-STAT3 in breast cancer cells, but the exact mechanism remained unknown. Herein, we show that MH-mediated inhibition of p-STAT3 in breast (MDA-MB-231) and lung (A549) cancer cell lines is accompanied by decreased levels of gp130 and p-JAK2, two upstream components of the IL-6 receptor (IL-6R) signaling pathway. Using an ELISA-based assay, we demonstrate that MH binds directly to IL-6Rα, significantly inhibiting (~60%) its binding to the IL-6 ligand. Importantly, no evidence of MH binding to two other cytokine receptors, IL-11Rα and IL-8R, was found. Moreover, MH did not alter the levels of tyrosine-phosphorylated or total Src family kinases, which are also constitutively activated in cancer cells, suggesting that signaling via other growth factor receptors is unaffected by MH. Binding of five major MH flavonoids (luteolin, quercetin, galangin, pinocembrin, and chrysin) was also tested, and all but pinocembrin could demonstrably bind IL-6Rα, partially (30–35%) blocking IL-6 binding at the highest concentration (50 μM) used. In agreement, each flavonoid inhibited p-STAT3 in a dose-dependent manner, with estimated IC50 values in the 3.5–70 μM range. Finally, docking analysis confirmed the capacity of each flavonoid to bind in an energetically favorable configuration to IL-6Rα at a site predicted to interfere with ligand binding. Taken together, our findings identify IL-6Rα as a direct target of MH and its flavonoids, highlighting IL-6R blockade as a mechanism for the anti-tumor activity of MH, as well as a viable therapeutic target in IL-6-dependent cancers.

25 June 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KRKhalil Ramadi
Khalil Ramadi
CDCanan Dagdeviren
Canan Dagdeviren
KSKevin C. Spencer
Kevin C. Spencer
PJPauline Joe
Pauline Joe
MCMax Cotler
Max Cotler
MCMichael J. Cima
Michael J. Cima
Significance: The brain is composed of distinct microstructures. Many neurologic and neuropsychiatric diseases arise from dysfunction of circuits of neurons and glia affecting multiple brain regions. Novel potential drug therapies are often delivered through acutely inserted cannulas in the brain. We show that such methods target a much larger region than focal chemical dosing using a class of chronically implanted microprobes. We develop techniques to quantify dynamics of deep-brain infusions and show distinct diffusion behavior of different chemicals. Our microprobes can be independently inserted and combine multiple fluidic lumens in a submillimeter footprint. Studies using implanted drug delivery systems in rodents illustrate our system’s ability to remotely control behavior and the importance of volume in modulating brain regions.